US20220008496A1 - Artificial tears and therapeutic uses - Google Patents
Artificial tears and therapeutic uses Download PDFInfo
- Publication number
- US20220008496A1 US20220008496A1 US17/329,586 US202117329586A US2022008496A1 US 20220008496 A1 US20220008496 A1 US 20220008496A1 US 202117329586 A US202117329586 A US 202117329586A US 2022008496 A1 US2022008496 A1 US 2022008496A1
- Authority
- US
- United States
- Prior art keywords
- oil
- ophthalmic composition
- composition
- weight
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000607 artificial tear Substances 0.000 title abstract description 5
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 101
- 239000003921 oil Substances 0.000 claims abstract description 83
- 235000019198 oils Nutrition 0.000 claims abstract description 83
- 239000004359 castor oil Substances 0.000 claims abstract description 43
- 235000019438 castor oil Nutrition 0.000 claims abstract description 43
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 41
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 34
- 206010013774 Dry eye Diseases 0.000 claims abstract description 34
- 241000124008 Mammalia Species 0.000 claims abstract description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 32
- 239000000839 emulsion Substances 0.000 claims description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 235000011187 glycerol Nutrition 0.000 claims description 14
- 239000004386 Erythritol Substances 0.000 claims description 13
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 13
- 239000008346 aqueous phase Substances 0.000 claims description 13
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 13
- 235000019414 erythritol Nutrition 0.000 claims description 13
- 229940009714 erythritol Drugs 0.000 claims description 13
- 229960005150 glycerol Drugs 0.000 claims description 13
- 229960004203 carnitine Drugs 0.000 claims description 11
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 239000000944 linseed oil Substances 0.000 claims description 9
- 235000021388 linseed oil Nutrition 0.000 claims description 9
- 229920005862 polyol Polymers 0.000 claims description 9
- 150000003077 polyols Chemical class 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 5
- 239000004327 boric acid Substances 0.000 claims description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 125000005430 oxychloro group Chemical group 0.000 claims description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 3
- 229920002675 Polyoxyl Polymers 0.000 claims 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 2
- 125000005250 alkyl acrylate group Chemical group 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 229940075529 glyceryl stearate Drugs 0.000 claims 2
- 229940089456 isopropyl stearate Drugs 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229960001855 mannitol Drugs 0.000 claims 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 claims 2
- 229960004063 propylene glycol Drugs 0.000 claims 2
- 235000013772 propylene glycol Nutrition 0.000 claims 2
- 229940114926 stearate Drugs 0.000 claims 2
- 239000000811 xylitol Substances 0.000 claims 2
- 235000010447 xylitol Nutrition 0.000 claims 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 2
- 229960002675 xylitol Drugs 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 235000008390 olive oil Nutrition 0.000 abstract description 22
- 239000004006 olive oil Substances 0.000 abstract description 22
- 235000005687 corn oil Nutrition 0.000 abstract description 7
- 239000002285 corn oil Substances 0.000 abstract description 6
- 235000011803 sesame oil Nutrition 0.000 abstract description 6
- 239000008159 sesame oil Substances 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 5
- 241000282326 Felis catus Species 0.000 abstract description 2
- 229940060184 oil ingredients Drugs 0.000 description 45
- 239000006196 drop Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 12
- 239000008213 purified water Substances 0.000 description 11
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 9
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 8
- 230000007480 spreading Effects 0.000 description 8
- 238000003892 spreading Methods 0.000 description 8
- 235000012424 soybean oil Nutrition 0.000 description 7
- 239000003549 soybean oil Substances 0.000 description 7
- 235000012343 cottonseed oil Nutrition 0.000 description 5
- 239000002385 cottonseed oil Substances 0.000 description 5
- 239000003889 eye drop Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 235000019483 Peanut oil Nutrition 0.000 description 4
- 235000004443 Ricinus communis Nutrition 0.000 description 4
- 235000019485 Safflower oil Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000004561 lacrimal apparatus Anatomy 0.000 description 4
- 239000000312 peanut oil Substances 0.000 description 4
- 229940053174 restasis Drugs 0.000 description 4
- 235000005713 safflower oil Nutrition 0.000 description 4
- 239000003813 safflower oil Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004397 blinking Effects 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000004489 tear production Effects 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920002274 Nalgene Polymers 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000004815 dispersion polymer Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 229960001518 levocarnitine Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000029147 Collagen-vascular disease Diseases 0.000 description 1
- 208000007775 Congenital alacrima Diseases 0.000 description 1
- 206010011013 Corneal erosion Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 206010011039 Corneal perforation Diseases 0.000 description 1
- 206010054760 Corneal thinning Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010015943 Eye inflammation Diseases 0.000 description 1
- 208000020564 Eye injury Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000036549 congenital autosomal dominant alacrima Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940028232 glycerin / polysorbate 80 Drugs 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Definitions
- the present invention is directed to artificial tears suitable for treating dry eye syndrome in a human or other mammal which comprises a mixture of castor oil with at least one other oil, for example a naturally occurring oil (e.g. olive oil, sesame oil, corn oil, etc.).
- a naturally occurring oil e.g. olive oil, sesame oil, corn oil, etc.
- Typical symptoms of keratoconjunctivitis or dry eye include feelings of dryness, burning, and a sandy-gritty eye sensation that can worsen during the day. Symptoms may also be described as itchy, scratchy, stingy or tired eyes. Other symptoms include pain, redness, a pulling sensation, and pressure behind the eye. The damage to the eye surface resulting from dry eye increases discomfort and sensitivity to bright light-and both eyes usually are affected.
- blinking coats the eye with tears, symptoms are worsened by activities in which the rate of blinking is reduced due to prolonged use of the eyes. These activities include prolonged reading, computer usage, driving or watching television. Symptoms increase in windy, dusty or smoky areas, in dry environments, high altitudes including airplanes, on days with low humidity, and in areas where an air conditioner, fan, or heater, is being used. Symptoms are less severe during cool, rainy, or foggy weather, and in humid places. Most people who have dry eyes experience mild irritation with no long-term effects. However, if the condition is left untreated or becomes severe, it can produce complications that can cause eye damage, resulting in impaired vision or possibly in the loss of vision.
- Having dry eyes for a prolonged period of time can lead to tiny abrasions on the surface of the eyes.
- the epithelium undergoes pathologic changes, namely squamous metaplasia and loss of goblet cells sometimes due to activation of T cells directed.
- Some severe cases result in thickening of the corneal surface, corneal erosion, punctate keratopathy, epithelial defects, corneal ulceration, corneal neovascularization, corneal scarring, corneal thinning, and even corneal perforation.
- An abnormality of any one of the three layers of tears which produces an unstable tear film may result in symptoms of keratitis sicca.
- Keratoconjunctivitis sicca is usually due to inadequate tear production.
- the aqueous tear layer is affected, resulting in aqueous tear deficiency or lacrimal hyposecretion.
- the lacrimal gland does not produce sufficient tears to keep the entire conjunctiva and cornea covered by a complete layer. This usually occurs in people who are otherwise healthy. Increased age is associated with decreased tearing. This is the most common type found in postmenopausal women.
- causes include idiopathic, congenital alacrima, xerophthalmia, lacrimal gland ablation, and sensory denervation.
- Sjogren's syndrome and autoimmune diseases associated with Sjogren's syndrome are also conditions associated with aqueous tear deficiency.
- Drugs such as isotretinoin, sedatives, diuretics, tricyclic antidepressants, antihypertensives, oral contraceptives, antihistamines, nasal decongestants, beta-blockers, phenothiazines, atropine, and pain relieving opiates such as morphine can cause or worsen this condition.
- Infiltration of the lacrimal glands by sarcoidosis or tumors, or postradiation fibrosis of the lacrimal glands can also cause this condition.
- Keratoconjunctivitis sicca can also be caused by abnormal tear composition resulting in rapid evaporation or premature destruction of the tears. When caused by rapid evaporation, it is termed evaporative dry eyes. In this condition, although the tear gland produces a sufficient amount of tears, the rate of evaporation of the tears is too rapid. There is a loss of water from the tears that results in tears that are too “salty” or hypertonic. As a result, the entire conjunctiva and cornea cannot be kept covered with a complete layer of tears during certain activities or in certain environments.
- Aging is one of the most common causes of dry eyes. This is due to the fact that tear production decreases with age. It may be caused by thermal or chemical burns, or by adenoviruses. Diabetics are also at increased risk for dry eye.
- An eye injury or other problem with the eyes or eyelids can cause keratoconjunctivitis sicca. Disorders of the eyelid can impair the complex blinking motion required to spread tears.
- Abnormalities of the lipid tear layer caused by blepharitis and rosacea, and abnormalities of the mucin tear layer caused by vitamin A deficiency, trachoma, diphtheric keratoconjunctivitis, mucocutaneous disorders and certain topical medications may cause dry eye or keratoconjunctivitis sicca.
- Dry eyes can usually be diagnosed by the symptoms alone. Tests can determine both the quantity and the quality of the tears. A slit lamp examination can be performed to diagnose dry eyes and to document any damage to the eye. A Schirmer's test can measure the amount of moisture bathing the eye. This test is useful for determining the severity of the condition.
- a variety of approaches can be taken to treatment, such as: avoidance of exacerbating factors, tear stimulation and supplementation, increasing tear retention, and eyelid cleansing and treatment of eye inflammation.
- Lubricating tear ointments can be used during the day, but they generally are used at bedtime due to poor vision after application. They contain white petrolatum, mineral oil, and similar lubricants. They serve as a lubricant and an emollient. Depending on the severity of the condition, ointments may be applied from every hour to just at bedtime. Ointments should not be used with contact lenses. Inflammation occurring in response to tears film hypertonicity can be suppressed by mild topical steroids or with topical immunosuppressants such as cyclosporine.
- Topical 0.05% cyclosporine A as a castor oil-based ophthalmic emulsion, is marketed in the United States by Allergan under the trade mark RESTASIS®.
- RESTASIS® decreases surface inflammation of the eye. It is thought to work through inhibition of transcription factors required for cytokine production and T-lymphocyte maturation. In a trial involving 1200 people, RESTASIS® increased tear production in 15% of people, compared to 5% with placebo. Usually, 1 drop of RESTASIS® is instilled in each eye twice a day, 12 hours apart.
- the present invention provides artificial tears which comprise a blend or mixture of castor oil with another oil, i.e. a food oil or healthy oil, such as olive oil, sesame oil, corn oil, soybean oil, safflower oil, cottonseed oil, peanut oil, etc.
- a food oil or healthy oil such as olive oil, sesame oil, corn oil, soybean oil, safflower oil, cottonseed oil, peanut oil, etc.
- Such blend of oils may be emulsified or dispersed in an aqueous phase, e.g. water, to provide a composition suitable for topical application to the eye of a mammal, suffering from dry eye, to relieve the symptoms thereof.
- the present invention provides a method for treating keratoconjunctivitis sicca (KCS) comprising providing the above composition, and administering said composition topically to the ocular surface or immediate vicinity of an eye of a patient.
- KCS keratoconjunctivitis sicca
- FIG. 1 shows the viscosities of varying mixtures of castor oil and olive oil at 25 and 37° C.
- the x axis refers to the percent castor oil in the oil mixture.
- Castor oil may be used in ophthalmic emulsion formulations for treating diseases and conditions of the eye because of its spreading properties. For example, it is believed that this ability to spread on an aqueous surface enables castor oil to form a thin layer on the ocular surface thereby reducing evaporation and helping alleviate symptoms of dry eye.
- oils referred to as ‘healthy oils’ or food oils, such as olive oil
- the spreading ability of these oils was found to be poor as compared to castor oil.
- Food oils or healthy oils are described in U.S. Patent Application Publication No. US2008/0070834 A1, which is hereby incorporated by reference.
- the oil mixtures of this invention comprise at least 5%, by weight, castor oil preferably at least 20%, by weight, castor oil.
- the oil mixtures of this invention comprise from 5 to 80%, by weight, castor oil and from 20 to 95%, by weight, of another oil, selected from the group of healthy oils or food oils, e.g. an oil selected from the group consisting of soybean oil, olive oil, safflower oil, corn oil, sesame oil, peanut oil and cotton seed oil, more preferably from 20 to 80%, by weight, castor oil and from 20 to 80%, by weight, of said other oil.
- the oil mixture of this invention comprises from 5 to 50%, by weight, castor oil and from 50 to 95%, by weight, of soybean oil, or the oil mixture of this invention comprises from 20 to 80%, by weight, castor oil and from 20 to 80%, by weight, olive oil, e.g. the oil mixture of this invention may comprise 70%, by weight, castor oil and 30%, by weight, olive oil.
- the oil mixture is preferably delivered to the eye in the form of an emulsion, including a micro emulsion, or a dispersion of said oil in a continuous aqueous phase, i.e. as an emulsion comprising from about 0.1 to 50%, by weight, oil and from 99.9 to 50%, by weight, of the aqueous phase, more preferably from about 0.1 to about 30%, by weight, oil and from about 99.9 to 70%, by weight, of the aqueous phase, e.g. about 0.25%, by weight, oil and about 99.75%, by weight, of the aqueous phase.
- emulsions of this invention may be prepared according to methods known in the art.
- emulsions may be prepared by methods disclosed in U.S. Pat. Nos. 4,649,047; 4,839,342 and 5,411,952 wherein emulsions of castor oil are disclosed. That is, the emulsions of this invention are prepared by the methods disclosed in U.S. Pat. Nos. 4,649,047; 4,839,342 and 5,411,952 wherein the above oil mixtures are substituted for castor oil.
- Such patents are hereby incorporated by reference herein.
- U.S. Pat. No. 5,474,979 discloses methods of preparing emulsions that are useful in treating dry eye.
- the emulsions of this patent are prepared by use of surfactants and dispersing agents which are especially suitable for preparing the emulsions of this invention.
- Such patent is hereby incorporated by reference herein.
- U.S. Patent Application Publication No. US2006/0106104 A1 discloses ophthalmic compositions which include compatible solute components, for example tonicity components, such as polyols and amino acids and, in particular, glycerin (glycerol), erythritol and carnitine.
- compatible solute components for example tonicity components, such as polyols and amino acids and, in particular, glycerin (glycerol), erythritol and carnitine.
- the ophthalmic compositions of this published patent application are useful for treating eyes that are exposed to hypertonic insult and, also, in a method of improving the visual acuity of a person in need thereof which comprises topically administering to said person, in an effective amount, said ophthalmic composition comprising a mixture of castor oil dispersed in an aqueous carrier component; and an effective amount of a tonicity component comprising a material selected from a combination of compatible solute agents.
- said combination of compatible solute agents may comprise two polyol components and one amino acid component and wherein said polyol components may be erythritol and glycerol and said amino acid component may be carnitine.
- the compositions include the tonicity components disclosed in the published patent application and, in particular, when the tonicity components are erythritol, glycerol and carnitine, the compositions of this invention are useful for treating eyes that are exposed to hypertonic insult.
- these tonicity components and, preferably, glycerin, erythritol and carnitine, may be included in the emulsions of this invention to provide an ophthalmic composition which may be applied topically to improve visual acuity.
- glycerin, erythritol and carnitine may be included in the emulsions of this invention to provide an ophthalmic composition which may be applied topically to improve visual acuity.
- compositions of this invention may be prepared as described in Example 1, below.
- the emulsion compositions of this invention may be manufactured with and without tonicity components, such as glycerin, erythritol, carnitine, etc.
- Part 1 an oil phase containing a mixture of castor oil and olive oil (non-sterile).
- Part 2 an aqueous phase containing purified water, polysorbate 80, and glycerin. Part 2 is sterile filtered using a sterile Nalgene filtration unit with a 0.2 ⁇ m PES membrane.
- Part 3 an aqueous polymer dispersion containing purified water and Pemulen® TR-2 (5 ⁇ Stock solution, 0.5%). Part 3 is sterilized by autoclaving at 121° C. for 15 minutes at 15 psig.
- Part 4 an aqueous polymer dispersion containing purified water and sodium carboxymethylcellulose. (5 ⁇ Stock solution, 2.5%). Part 4 is sterilized by autoclaving at 121° C. for 15 minutes at 15 psig.
- Part 5 an aqueous phase containing purified water, erythritol, levocarnitine, boric acid, Sodium Hydroxide (pH adjustment), and purite (preservative).
- Part 5 is sterile filtered using a sterile Nalgene filtration unit with a 0.2 ⁇ m PES membrane.
- Part 5 can be modified based on formulation vehicle, see Table 1.
- Part 1 is added to Part 2 and the mixture is homogenized at 60°-70° C. for 60 minutes at 14-15 Krpm.
- Part 1 and Part 2 is mixed using a Polytron PT 3100 homogenizer with a rotostator style tool ( ⁇ 30 mm head).
- the homogenizing step takes place in a laminar flow hood as do all subsequent manufacturing steps.
- the premix is cooled to 30° C. and Part 3 is added while mixing at low speed using a magnetic stir bar.
- Part 4 is then added while similarly mixing at a slow speed using a magnetic stir bar.
- Part 5 is added under light protection using a similar mode of mixing.
- the emulsion, protected from light from this point forward, is mixed at a low speed for a specified period of time ( ⁇ 30 minutes) to form the final bulk emulsion.
- Part 1 & 2 800 g (oil/glycerin/PolySorbate 80)
- Part 4 400 g (2.5% (w/w) Na carboxymethylcellulose—5 ⁇ Stock))
- the mixture of oils used in the ophthalmic compositions of this invention may be evaluated as described in Example 2, below.
- “Model Tear Solution”, described in Table 2, below, is added to of a small cell culture dish (25 mm ⁇ 10 mm style) in an amount sufficient to cover the bottom thereof. Amount should be ⁇ 2.5 mL); 2.
- One drop of oil mixture (10 to 50 ⁇ l drop size) is added to said dish and an observation of how readily the drop disperses on the surface of the tear solution is made for not less than 60 seconds; 3.
- the drop dispersed on the tear solution surface is mixed with a spatula and how readily the drop disperses in the tear solution is observed; and, 4.
- the mixed oil and tear solution observe for several minutes/hours to see if oil coalesces.
- Model Tear Solution Ingredient Conc. (% w/v) Sodium Chloride 0.90 Calcium Chloride, Dihydrate 0.015 Sodium Phosphate Dibasic, Heptahydrate 0.028 Lysozyme, egg white 0.19 Albumin, bovine 0.020 Gamma-Globulin, human 0.010 Mucin, bovine submaxillary 0.020 1N HCl and/or 1N NaOH Adj. to pH 7.2 Purified Water Q.S.
- ophthalmic compositions of the present invention were evaluated in an in-vivo study as described in Example 3, below.
- the oil mixture was utilized as a vehicle for the tonicity components carnitine, glycerine and erythritol.
- Female New Zealand White rabbits (5 rabbits/group) were given one drop ( ⁇ 40 ⁇ L each drop) of said emulsion of or a marketed, comparator eye drop, comprising 1.25%, by weight, castor oil, emulsified in an aqueous phase, by topical ocular instillation in the left eye (OS), 6 times daily (approximately 1 hr intervals) for one day.
- OS left eye
- the contralateral right eye (OD) served as a control without eye drop instillation.
- the following parameters were evaluated: viability, clinical observations, ocular discomfort, gross ocular observations (irritation), and ophthalmic examination (slit lamp biomicroscopy, pupillary reflex).
- Ocular instillation of the emulsion of the invention caused a minimal discomfort response with duration of up to 30 sec (70% frequency) or 30 to 60 sec (7% frequency).
- the comparator eye drop caused a minimal discomfort response with duration of up to 30 sec (57% frequency) or 30 to 60 sec (13% frequency).
- the comparator eye drop caused mild (+1) or moderate (+2) conjunctival congestion (hyperemia) with 50% or 3% frequency, respectively.
- the emulsion of this invention caused equivalent minimal, transient discomfort and significantly less mild conjunctival hyperemia compared to a marketed, comparator eye drop.
- Emulsion of Oil Mixture and Comparator Emulsion Formulations 0.25% Castor/Olive 1.25% Castor Ingredients (70/30) Oil Ingredients % (w/w) % (w/w) Castor Oil 0.175 1.25 Olive Oil, Super Refined (Croda) 0.075 — Polysorbate 80, Super Refined (Croda) 0.5 — Polysorbate 80 — 1.0 Carboxymethylcellulose 0.5 — Sodium (Low Viscosity, 7LFPH) Pemulen TR-2 0.1 0.1 Glycerin 1.0 1.0 Purite 0.01 0.0075 Boric Acid 0.6 0.6 Erythritol 0.25 — Levocarnitine 0.25 — 5N NaOH and/or 5N NaOH Ad pH to 7.3 Ad pH to 7.3 Purified Water QS QS
- olive oil further reduces the viscosity of castor oil to 105 cps and 95 cps at 37° C., respectively, and 220 cps and 150 cps at 25° C., respectively.
- compositions of the invention can be administrated topically to various mammalian species suffering from dry eye, e.g., humans, cats, dogs and the like in an effective amount to relieve the symptoms of dry eye, as needed or on a regimen in single or 2 to 4 daily doses.
- the above mixtures of castor oil with a healthy oil may be advantageously, used in combination with various tonicity improving compounds.
- the combination of one of the oil mixtures, described above, with a tonicity to component may be used to treat dry eye and improve the visual acuity of a person in need of said treatment, by topically administering to said person, in an effective amount, an ophthalmic composition comprising said oil mixture dispersed in an aqueous carrier component; and an effective amount of a tonicity component comprising a material selected from a combination of compatible solute agents, wherein said combination of compatible solute agents comprises two polyol components and one amino acid component and wherein said polyol components are erythritol and glycerol and said amino acid component is carnitine.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides ophthalmic compositions, e.g. artificial tears, suitable for treating dry eye syndrome in a human or other mammal suffering there from, e.g. a dog or cat, which comprise a mixture of castor oil with another oil, e.g. a food oil, e. g. olive oil, sesame oil, corn oil etc.
Description
- This application is a continuation of U.S. patent application Ser. No. 15/791,158, filed Oct. 23, 2017, which is a continuation of U.S. patent application Ser. No. 14/166,589, filed Jan. 28, 2014, now U.S. Pat. No. 9,821,020, issued Nov. 21, 2017, which is a continuation of U.S. patent application Ser. No. 13/931,281, filed Jun. 28, 2013, now U.S. Pat. No. 8,679,554, issued Mar. 25, 2014, which is a continuation of U.S. patent application Ser. No. 13/376,374, filed Dec. 5, 2011, now U.S. Pat. No. 8,496,976, issued Jul. 30, 2013, which is a national stage application under 35 U.S.C. § 371 of PCT Patent Application Serial No. PCT/US10/37153, filed Jun. 3, 2010, which claims the benefit of U.S. Provisional Patent Application Ser. Number 61/184,339, filed Jun. 5, 2009, all of which are hereby incorporated by reference in their entireties.
- The present invention is directed to artificial tears suitable for treating dry eye syndrome in a human or other mammal which comprises a mixture of castor oil with at least one other oil, for example a naturally occurring oil (e.g. olive oil, sesame oil, corn oil, etc.).
- Typical symptoms of keratoconjunctivitis or dry eye include feelings of dryness, burning, and a sandy-gritty eye sensation that can worsen during the day. Symptoms may also be described as itchy, scratchy, stingy or tired eyes. Other symptoms include pain, redness, a pulling sensation, and pressure behind the eye. The damage to the eye surface resulting from dry eye increases discomfort and sensitivity to bright light-and both eyes usually are affected.
- Because blinking coats the eye with tears, symptoms are worsened by activities in which the rate of blinking is reduced due to prolonged use of the eyes. These activities include prolonged reading, computer usage, driving or watching television. Symptoms increase in windy, dusty or smoky areas, in dry environments, high altitudes including airplanes, on days with low humidity, and in areas where an air conditioner, fan, or heater, is being used. Symptoms are less severe during cool, rainy, or foggy weather, and in humid places. Most people who have dry eyes experience mild irritation with no long-term effects. However, if the condition is left untreated or becomes severe, it can produce complications that can cause eye damage, resulting in impaired vision or possibly in the loss of vision.
- Having dry eyes for a prolonged period of time can lead to tiny abrasions on the surface of the eyes. In advanced cases, the epithelium undergoes pathologic changes, namely squamous metaplasia and loss of goblet cells sometimes due to activation of T cells directed. Some severe cases result in thickening of the corneal surface, corneal erosion, punctate keratopathy, epithelial defects, corneal ulceration, corneal neovascularization, corneal scarring, corneal thinning, and even corneal perforation. An abnormality of any one of the three layers of tears which produces an unstable tear film, may result in symptoms of keratitis sicca.
- Keratoconjunctivitis sicca is usually due to inadequate tear production. The aqueous tear layer is affected, resulting in aqueous tear deficiency or lacrimal hyposecretion. The lacrimal gland does not produce sufficient tears to keep the entire conjunctiva and cornea covered by a complete layer. This usually occurs in people who are otherwise healthy. Increased age is associated with decreased tearing. This is the most common type found in postmenopausal women. Causes include idiopathic, congenital alacrima, xerophthalmia, lacrimal gland ablation, and sensory denervation. In rare cases, it may be a symptom of collagen vascular diseases, including rheumatoid arthritis, Wegener's granulomatosis, and systemic lupus erythematosus. Sjogren's syndrome and autoimmune diseases associated with Sjogren's syndrome are also conditions associated with aqueous tear deficiency. Drugs such as isotretinoin, sedatives, diuretics, tricyclic antidepressants, antihypertensives, oral contraceptives, antihistamines, nasal decongestants, beta-blockers, phenothiazines, atropine, and pain relieving opiates such as morphine can cause or worsen this condition. Infiltration of the lacrimal glands by sarcoidosis or tumors, or postradiation fibrosis of the lacrimal glands can also cause this condition.
- Keratoconjunctivitis sicca can also be caused by abnormal tear composition resulting in rapid evaporation or premature destruction of the tears. When caused by rapid evaporation, it is termed evaporative dry eyes. In this condition, although the tear gland produces a sufficient amount of tears, the rate of evaporation of the tears is too rapid. There is a loss of water from the tears that results in tears that are too “salty” or hypertonic. As a result, the entire conjunctiva and cornea cannot be kept covered with a complete layer of tears during certain activities or in certain environments.
- Aging is one of the most common causes of dry eyes. This is due to the fact that tear production decreases with age. It may be caused by thermal or chemical burns, or by adenoviruses. Diabetics are also at increased risk for dry eye.
- An eye injury or other problem with the eyes or eyelids, such as bulging eyes or a drooping eyelid, can cause keratoconjunctivitis sicca. Disorders of the eyelid can impair the complex blinking motion required to spread tears.
- About half of all people who wear contact lenses have dry eyes. This is because soft contact lenses, which float on the tear film that covers the cornea, absorb the tears in the eyes. Dry eye also occurs or gets worse after refractive surgeries, in which the corneal nerves are cut during the creation of a corneal flap, because the corneal nerves stimulate tear secretion. Dry eyes caused by these procedures usually disappear after several months.
- Abnormalities of the lipid tear layer caused by blepharitis and rosacea, and abnormalities of the mucin tear layer caused by vitamin A deficiency, trachoma, diphtheric keratoconjunctivitis, mucocutaneous disorders and certain topical medications may cause dry eye or keratoconjunctivitis sicca.
- Dry eyes can usually be diagnosed by the symptoms alone. Tests can determine both the quantity and the quality of the tears. A slit lamp examination can be performed to diagnose dry eyes and to document any damage to the eye. A Schirmer's test can measure the amount of moisture bathing the eye. This test is useful for determining the severity of the condition.
- A variety of approaches can be taken to treatment, such as: avoidance of exacerbating factors, tear stimulation and supplementation, increasing tear retention, and eyelid cleansing and treatment of eye inflammation.
- For mild and moderate cases, supplemental lubrication is the most important part of treatment. Application of artificial tears every few hours can provide temporary relief.
- Lubricating tear ointments can be used during the day, but they generally are used at bedtime due to poor vision after application. They contain white petrolatum, mineral oil, and similar lubricants. They serve as a lubricant and an emollient. Depending on the severity of the condition, ointments may be applied from every hour to just at bedtime. Ointments should not be used with contact lenses. Inflammation occurring in response to tears film hypertonicity can be suppressed by mild topical steroids or with topical immunosuppressants such as cyclosporine.
- Topical 0.05% cyclosporine A, as a castor oil-based ophthalmic emulsion, is marketed in the United States by Allergan under the trade mark RESTASIS®. RESTASIS® decreases surface inflammation of the eye. It is thought to work through inhibition of transcription factors required for cytokine production and T-lymphocyte maturation. In a trial involving 1200 people, RESTASIS® increased tear production in 15% of people, compared to 5% with placebo. Usually, 1 drop of RESTASIS® is instilled in each eye twice a day, 12 hours apart.
- The present invention provides artificial tears which comprise a blend or mixture of castor oil with another oil, i.e. a food oil or healthy oil, such as olive oil, sesame oil, corn oil, soybean oil, safflower oil, cottonseed oil, peanut oil, etc. Such blend of oils may be emulsified or dispersed in an aqueous phase, e.g. water, to provide a composition suitable for topical application to the eye of a mammal, suffering from dry eye, to relieve the symptoms thereof. Furthermore, the present invention provides a method for treating keratoconjunctivitis sicca (KCS) comprising providing the above composition, and administering said composition topically to the ocular surface or immediate vicinity of an eye of a patient.
-
FIG. 1 shows the viscosities of varying mixtures of castor oil and olive oil at 25 and 37° C. In this figure the x axis refers to the percent castor oil in the oil mixture. - Castor oil may be used in ophthalmic emulsion formulations for treating diseases and conditions of the eye because of its spreading properties. For example, it is believed that this ability to spread on an aqueous surface enables castor oil to form a thin layer on the ocular surface thereby reducing evaporation and helping alleviate symptoms of dry eye. There is a high level of interest in using other oils (referred to as ‘healthy oils’ or food oils, such as olive oil) in ocular formulas for dry eye treatment. However, the spreading ability of these oils was found to be poor as compared to castor oil. (Food oils or healthy oils are described in U.S. Patent Application Publication No. US2008/0070834 A1, which is hereby incorporated by reference.)
- When a drop of castor oil is added over the surface of water or model tear solution, it spreads quickly, forming a thin layer on the surface of the aqueous fluid. In contrast, other oils, such as soybean oil, olive oil, safflower oil, corn oil, sesame oil, peanut oil and cotton seed oil do not spread over the surface of either water or model tear solution, even after overnight application.
- It has now been surprisingly found that even small amounts of castor oil added to the ‘healthy oils’ improves the spreading properties of these oils. It is believed that the improvement in dispersion obtained by using the mixture of castor oil with healthy oils helps the delivery of these more desired oils when placed on the ocular surface in treatment of dry eye.
- An additional benefit in using the above blend or mixture of oils is the reduction of viscosity of castor oil when combined with other, less viscous oils. Surprisingly, this drop-in viscosity was found to be non-linear and allows for selection of a formula of oil mixtures, with improved spreading and lower viscosity which is favorable for use in treatment of dry eye.
- The oil mixtures of this invention comprise at least 5%, by weight, castor oil preferably at least 20%, by weight, castor oil. In particular, the oil mixtures of this invention comprise from 5 to 80%, by weight, castor oil and from 20 to 95%, by weight, of another oil, selected from the group of healthy oils or food oils, e.g. an oil selected from the group consisting of soybean oil, olive oil, safflower oil, corn oil, sesame oil, peanut oil and cotton seed oil, more preferably from 20 to 80%, by weight, castor oil and from 20 to 80%, by weight, of said other oil.
- Most preferably, the oil mixture of this invention comprises from 5 to 50%, by weight, castor oil and from 50 to 95%, by weight, of soybean oil, or the oil mixture of this invention comprises from 20 to 80%, by weight, castor oil and from 20 to 80%, by weight, olive oil, e.g. the oil mixture of this invention may comprise 70%, by weight, castor oil and 30%, by weight, olive oil.
- The oil mixture is preferably delivered to the eye in the form of an emulsion, including a micro emulsion, or a dispersion of said oil in a continuous aqueous phase, i.e. as an emulsion comprising from about 0.1 to 50%, by weight, oil and from 99.9 to 50%, by weight, of the aqueous phase, more preferably from about 0.1 to about 30%, by weight, oil and from about 99.9 to 70%, by weight, of the aqueous phase, e.g. about 0.25%, by weight, oil and about 99.75%, by weight, of the aqueous phase.
- The emulsions of this invention may be prepared according to methods known in the art. For example, emulsions may be prepared by methods disclosed in U.S. Pat. Nos. 4,649,047; 4,839,342 and 5,411,952 wherein emulsions of castor oil are disclosed. That is, the emulsions of this invention are prepared by the methods disclosed in U.S. Pat. Nos. 4,649,047; 4,839,342 and 5,411,952 wherein the above oil mixtures are substituted for castor oil. Such patents are hereby incorporated by reference herein.
- As disclosed in U.S. Pat. Nos. 4,649,047; 4,839,342 and 5,411,952, said emulsions of castor oil are disclosed as vehicles for cyclosporine. Similarly, the oil mixtures of the present invention may be used as vehicles for cyclosporine. Such patents are hereby incorporated by reference herein.
- In addition, U.S. Pat. No. 5,474,979 discloses methods of preparing emulsions that are useful in treating dry eye. The emulsions of this patent are prepared by use of surfactants and dispersing agents which are especially suitable for preparing the emulsions of this invention. Such patent is hereby incorporated by reference herein.
- Finally, U.S. Patent Application Publication No. US2006/0106104 A1 discloses ophthalmic compositions which include compatible solute components, for example tonicity components, such as polyols and amino acids and, in particular, glycerin (glycerol), erythritol and carnitine. The ophthalmic compositions of this published patent application are useful for treating eyes that are exposed to hypertonic insult and, also, in a method of improving the visual acuity of a person in need thereof which comprises topically administering to said person, in an effective amount, said ophthalmic composition comprising a mixture of castor oil dispersed in an aqueous carrier component; and an effective amount of a tonicity component comprising a material selected from a combination of compatible solute agents.
- For example, said combination of compatible solute agents may comprise two polyol components and one amino acid component and wherein said polyol components may be erythritol and glycerol and said amino acid component may be carnitine. In the embodiment of the present invention, wherein the compositions include the tonicity components disclosed in the published patent application and, in particular, when the tonicity components are erythritol, glycerol and carnitine, the compositions of this invention are useful for treating eyes that are exposed to hypertonic insult. Similarly, these tonicity components and, preferably, glycerin, erythritol and carnitine, may be included in the emulsions of this invention to provide an ophthalmic composition which may be applied topically to improve visual acuity. Such patent application is hereby incorporated by reference herein.
- The compositions of this invention may be prepared as described in Example 1, below.
- As disclosed below, the emulsion compositions of this invention may be manufactured with and without tonicity components, such as glycerin, erythritol, carnitine, etc.
- Batches were manufactured on a weight basis from pre-weighed compendial raw materials in five parts:
- Part 1: an oil phase containing a mixture of castor oil and olive oil (non-sterile).
- Part 2: an aqueous phase containing purified water,
polysorbate 80, and glycerin. Part 2 is sterile filtered using a sterile Nalgene filtration unit with a 0.2 μm PES membrane. - Part 3: an aqueous polymer dispersion containing purified water and Pemulen® TR-2 (5×Stock solution, 0.5%). Part 3 is sterilized by autoclaving at 121° C. for 15 minutes at 15 psig.
- Part 4: an aqueous polymer dispersion containing purified water and sodium carboxymethylcellulose. (5×Stock solution, 2.5%). Part 4 is sterilized by autoclaving at 121° C. for 15 minutes at 15 psig.
- Part 5: an aqueous phase containing purified water, erythritol, levocarnitine, boric acid, Sodium Hydroxide (pH adjustment), and purite (preservative). Part 5 is sterile filtered using a sterile Nalgene filtration unit with a 0.2 μm PES membrane. Part 5 can be modified based on formulation vehicle, see Table 1.
- Procedure: Part 1 is added to Part 2 and the mixture is homogenized at 60°-70° C. for 60 minutes at 14-15 Krpm. Part 1 and Part 2 is mixed using a Polytron PT 3100 homogenizer with a rotostator style tool (˜30 mm head). The homogenizing step takes place in a laminar flow hood as do all subsequent manufacturing steps. The premix is cooled to 30° C. and Part 3 is added while mixing at low speed using a magnetic stir bar. Part 4 is then added while similarly mixing at a slow speed using a magnetic stir bar. Part 5 is added under light protection using a similar mode of mixing. The emulsion, protected from light from this point forward, is mixed at a low speed for a specified period of time (˜30 minutes) to form the final bulk emulsion.
- Following the manufacturing procedure as previously outlined, the following are combined:
- Part 1 & 2: 800 g (oil/glycerin/PolySorbate 80)
- Part 3: 400 g (0.5% (w/w) Pemulen TR-2-5×Stock)
- Part 4: 400 g (2.5% (w/w) Na carboxymethylcellulose—5×Stock))
- Part 5: 400 g (buffer/without ions/purite—5×Stock)
- Batch Size: 2,000 g
-
TABLE 1 Composition of Emulsion Ingredients 0.25% Castor/Olive Oil (70:30) Ingredients % (w/w) PART 1 Castor/Olive Oil (70:30) 0.25 PART 2 Purified Water ~40 Polysorbate 800.5 Glycerin 1.0 PART 3 (0.5% Stock Solution) Purified Water ~20 Pemulen TR-2 0.1 PART 4 (2.5% Stock Solution) Purified Water ~20 Carboxymethylcellulose Sodium 0.5 (Low Viscosity) PART 5 (5X Stock Solution) Purified Water ~20 Boric Acid 0.6 Erythritol 0.25 Carnitine 0.25 Sodium Hydroxide, 5N Adjust to pH 7.3 Stabilized Oxychloro complex 0.01 (Purite) Purified Water Q.S. - The mixture of oils used in the ophthalmic compositions of this invention may be evaluated as described in Example 2, below.
- 1. “Model Tear Solution”, described in Table 2, below, is added to of a small cell culture dish (25 mm×10 mm style) in an amount sufficient to cover the bottom thereof. Amount should be ˜2.5 mL);
2. One drop of oil mixture (10 to 50 μl drop size) is added to said dish and an observation of how readily the drop disperses on the surface of the tear solution is made for not less than 60 seconds;
3. The drop dispersed on the tear solution surface is mixed with a spatula and how readily the drop disperses in the tear solution is observed; and,
4. The mixed oil and tear solution observe for several minutes/hours to see if oil coalesces. -
TABLE 2 Composition of Model Tear Solution Ingredient Conc. (% w/v) Sodium Chloride 0.90 Calcium Chloride, Dihydrate 0.015 Sodium Phosphate Dibasic, Heptahydrate 0.028 Lysozyme, egg white 0.19 Albumin, bovine 0.020 Gamma-Globulin, human 0.010 Mucin, bovine submaxillary 0.020 1N HCl and/or 1N NaOH Adj. to pH 7.2 Purified Water Q.S. - Using the above procedure, the following oils and mixtures of oils are tested and the results reported in Table 3, below.
-
TABLE 3 Spreading behavior observed for oils when added to model tear solution Observation after addition of Oil composition 1 drop to model tear solution Single oils Castor oil Drop disperses readily on contact with tear solution, remains dispersed overnight, no coalescence Soybean oil Drop does not disperse, even after overnight time period Olive oil Drop does not disperse, even after overnight time period Safflower oil Drop does not disperse, even after overnight time period Corn oil Drop does not disperse, even after overnight time period Sesame oil Drop does not disperse, even after overnight time period Peanut oil Drop does not disperse, even after overnight time period Cottonseed oil Drop does not disperse, even after overnight time period Oil mixture Castor 5:95 ratio Drop disperses readily on contact with tear solution oil + Soybean oil 10:90 ratio Drop disperses readily on contact with tear solution 20:80 ratio Drop disperses readily on contact with tear solution 50:50 ratio Drop disperses readily on contact with tear solution Oil mixture Castor 20:80 ratio Drop disperses readily on contact with tear solution oil + Olive oil 40:60 ratio Drop disperses readily on contact with tear solution 60:40 ratio Drop disperses readily on contact with tear solution 80:20 ratio Drop disperses readily on contact with tear solution - As shown in Table 2, the addition of minor amounts of castor oil, to an oil which does not spread on a model of an ocular surface causes the spreading across ocular surface. In particular, the addition of as little as 5%, by weight, castor oil, to soybean oil causes the spreading of the resulting oil mixture across ocular surface. The addition of as little as 20%, by weight, castor oil, to olive oil causes the spreading of the resulting oil mixture across ocular surface.
- The ophthalmic compositions of the present invention were evaluated in an in-vivo study as described in Example 3, below.
- A 1-day ocular tolerability study of an emulsion comprising 0.25%, by weight, of a 70/30 castor oil/olive oil mixture, manufactured according to Example 1, was conducted in rabbits. The oil mixture was utilized as a vehicle for the tonicity components carnitine, glycerine and erythritol. Female New Zealand White rabbits (5 rabbits/group) were given one drop (˜40 μL each drop) of said emulsion of or a marketed, comparator eye drop, comprising 1.25%, by weight, castor oil, emulsified in an aqueous phase, by topical ocular instillation in the left eye (OS), 6 times daily (approximately 1 hr intervals) for one day. The contralateral right eye (OD) served as a control without eye drop instillation. The following parameters were evaluated: viability, clinical observations, ocular discomfort, gross ocular observations (irritation), and ophthalmic examination (slit lamp biomicroscopy, pupillary reflex). Ocular instillation of the emulsion of the invention caused a minimal discomfort response with duration of up to 30 sec (70% frequency) or 30 to 60 sec (7% frequency). The comparator eye drop caused a minimal discomfort response with duration of up to 30 sec (57% frequency) or 30 to 60 sec (13% frequency). There were no effects of ocular instillation of the above emulsion on gross ocular observations (irritation). The comparator eye drop, caused mild (+1) or moderate (+2) conjunctival congestion (hyperemia) with 50% or 3% frequency, respectively. In conclusion, the emulsion of this invention caused equivalent minimal, transient discomfort and significantly less mild conjunctival hyperemia compared to a marketed, comparator eye drop.
-
TABLE 4 Composition of Emulsion of Oil Mixture and Comparator Emulsion Formulations 0.25% Castor/Olive 1.25% Castor Ingredients (70/30) Oil Ingredients % (w/w) % (w/w) Castor Oil 0.175 1.25 Olive Oil, Super Refined (Croda) 0.075 — Polysorbate 80, Super Refined (Croda)0.5 — Polysorbate 80— 1.0 Carboxymethylcellulose 0.5 — Sodium (Low Viscosity, 7LFPH) Pemulen TR-2 0.1 0.1 Glycerin 1.0 1.0 Purite 0.01 0.0075 Boric Acid 0.6 0.6 Erythritol 0.25 — Levocarnitine 0.25 — 5N NaOH and/or 5N NaOH Ad pH to 7.3 Ad pH to 7.3 Purified Water QS QS - The viscosity of mixtures of the oils used in the compositions and method of this invention were determined as described in Example 4, below.
- Mixtures of Castor oil and olive oil were prepared and the viscosities thereof were determined. The results are reported in
FIG. 1 . As shown. The change in viscosity is nonlinear, i.e. discontinuous. Surprisingly, small amounts of olive oil reduce the viscosity to a greater extent than larger amounts. That is, 10 and 20%, by weight, olive oil reduces the viscosity of castor oil from 675 cps to 510 cps and 390 cps at 25° C., respectively and from 305 cps to 230 cps and 195 cps at 37° C., respectively. By comparison, 60 and 40%, by weight, olive oil further reduces the viscosity of castor oil to 105 cps and 95 cps at 37° C., respectively, and 220 cps and 150 cps at 25° C., respectively. Thus, the advantages of using castor oil, alone, while substantially reducing the viscosity thereof is obtained by the addition of small amounts of another oil, e.g. olive oil. - The compositions of the invention can be administrated topically to various mammalian species suffering from dry eye, e.g., humans, cats, dogs and the like in an effective amount to relieve the symptoms of dry eye, as needed or on a regimen in single or 2 to 4 daily doses.
- The foregoing description details specific methods and compositions that can be employed to practice the present invention, and represents the best mode contemplated. While the above invention has been described with reference to the compositions, above, the oils described below may be included within the scope of this invention:
- linseed oil;
- eucalyptus oil;
- sunflower oil;
- peppermint oil;
- rosemary oil;
- caraway oil;
- rapeseed oil;
- maize oil;
- cottonseed oil;
- arachis oil; and
- almond oil.
- In addition, the above mixtures of castor oil with a healthy oil, may be advantageously, used in combination with various tonicity improving compounds. In particular, the combination of one of the oil mixtures, described above, with a tonicity to component, may be used to treat dry eye and improve the visual acuity of a person in need of said treatment, by topically administering to said person, in an effective amount, an ophthalmic composition comprising said oil mixture dispersed in an aqueous carrier component; and an effective amount of a tonicity component comprising a material selected from a combination of compatible solute agents, wherein said combination of compatible solute agents comprises two polyol components and one amino acid component and wherein said polyol components are erythritol and glycerol and said amino acid component is carnitine.
- Thus, however detailed the foregoing may appear in text, it should not be construed as limiting the overall scope hereof; rather, the ambit of the present invention is to be governed only by the lawful construction of the appended claims.
Claims (23)
1. An ophthalmic composition comprising:
an oil mixture forming a stabilized oil emulsion in an aqueous phase, the oil mixture consisting essentially of linseed oil and castor oil;
one or more surfactants; and,
water;
wherein the ophthalmic composition is effective for the treatment of dry eye syndrome in a human or mammal in need thereof.
2. The ophthalmic composition of claim 1 , wherein the oil mixture is an emulsion comprising between 0.1% to 10% by weight of the aqueous phase.
3. The ophthalmic composition of claim 2 , wherein the oil mixture is an emulsion comprising between 0.1% to 1.25% by weight of the aqueous phase.
4. The ophthalmic composition of claim 2 , wherein the oil mixture is an emulsion comprising between 0.1 to 0.5% by weight of the aqueous phase.
5. The ophthalmic composition of claim 1 , wherein the amount of linseed oil in the oil mixture comprises between 5 to 95% by weight of linseed oil.
6. The ophthalmic composition of claim 1 , wherein the amount of linseed oil in the oil mixture comprises between 20 to 80% by weight of linseed oil.
7. The ophthalmic composition of claim 1 , wherein the oil mixture comprises between 40 to 60% by weight of linseed oil.
8. The ophthalmic composition of claim 1 , wherein the one or more surfactants are selected from the group consisting of polysorbate, polyoxyl stearate, glyceryl stearate, and isopropyl stearate.
9. The ophthalmic composition of claim 1 , further comprising one or more tonicity agents.
10. The ophthalmic composition of claim 9 , wherein the one or more tonicity agents are selected from the group consisting of polyols and amino acids.
11. The ophthalmic composition of claim 10 , wherein the polyols are selected from the group consisting of glycerin, mannitol, xylitol, propylene glycol, and erythritol.
12. The ophthalmic composition of claim 10 , wherein the amino acid is carnitine.
13. The ophthalmic composition of claim 1 , further comprising one or more viscosity enhancers.
14. The ophthalmic composition of claim 13 , wherein the one or more viscosity enhancers are selected from the group consisting of carboxymethyl cellulose and crosslinked copolymers of acrylic acid and C10-C30 alkyl acrylate.
15. The ophthalmic composition of claim 1 , further comprising one or more acids or bases selected from the group consisting of hydrochloric acid, sodium hydroxide, and boric acid.
16. The ophthalmic composition of claim 1 , further comprising at least one preservative.
17. The ophthalmic composition of claim 16 , wherein the preservative comprises stabilized oxychloro complex.
18. A method for treating keratoconjunctivitis sicca (KCS) comprising:
providing an ophthalmic composition for the treatment of KCS, the composition comprising:
an oil mixture forming a stabilized oil emulsion in an aqueous phase, the oil mixture consisting essentially of linseed oil and castor oil;
one or more surfactants;
one or more tonicity agents; and,
water;
administering said composition topically to the ocular surface or immediate vicinity of an eye of a patient in need thereof.
19. The method of claim 18 , wherein the one or more surfactants are selected from the group consisting of polysorbate, polyoxyl stearate, glyceryl stearate, and isopropyl stearate.
20. The method of claim 18 , wherein the one or more tonicity agents are selected from the group consisting of polyols and amino acids.
21. The method of claim 20 , wherein the polyols are selected from the group consisting of glycerin, mannitol, xylitol, propylene glycol, and erythritol.
22. The method of claim 20 , wherein the amino acid is carnitine.
23. A composition for treating an eye in need thereof, the composition comprising:
an oil mixture consisting essentially of linseed oil and castor oil;
carboxymethyl cellulose;
glycerin;
polysorbate 80;
crosslinked copolymers of acrylic acid and C10-C30 alkyl acrylate;
polyoxyl stearate;
carnitine;
erythritol;
boric acid; and,
water.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/329,586 US20220008496A1 (en) | 2009-06-05 | 2021-05-25 | Artificial tears and therapeutic uses |
US18/364,692 US20240108677A1 (en) | 2009-06-05 | 2023-08-03 | Artificial tears and therapeutic uses |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18433909P | 2009-06-05 | 2009-06-05 | |
PCT/US2010/037153 WO2010141648A2 (en) | 2009-06-05 | 2010-06-03 | Artificial tears and therapeutic uses |
US201213376374A | 2012-04-27 | 2012-04-27 | |
US13/931,281 US8679554B2 (en) | 2009-06-05 | 2013-06-28 | Artificial tears and therapeutic uses |
US14/166,589 US9821020B2 (en) | 2009-06-05 | 2014-01-28 | Artificial tears and therapeutic uses |
US15/791,158 US11045515B2 (en) | 2009-06-05 | 2017-10-23 | Artificial tears and therapeutic uses |
US17/329,586 US20220008496A1 (en) | 2009-06-05 | 2021-05-25 | Artificial tears and therapeutic uses |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/791,158 Continuation US11045515B2 (en) | 2009-06-05 | 2017-10-23 | Artificial tears and therapeutic uses |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/364,692 Continuation US20240108677A1 (en) | 2009-06-05 | 2023-08-03 | Artificial tears and therapeutic uses |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220008496A1 true US20220008496A1 (en) | 2022-01-13 |
Family
ID=42312750
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/376,374 Active US8496976B2 (en) | 2009-06-05 | 2010-06-03 | Artificial tears and therapeutic uses |
US13/931,281 Active US8679554B2 (en) | 2009-06-05 | 2013-06-28 | Artificial tears and therapeutic uses |
US14/166,589 Active 2031-03-12 US9821020B2 (en) | 2009-06-05 | 2014-01-28 | Artificial tears and therapeutic uses |
US15/791,158 Active 2031-03-02 US11045515B2 (en) | 2009-06-05 | 2017-10-23 | Artificial tears and therapeutic uses |
US17/329,586 Abandoned US20220008496A1 (en) | 2009-06-05 | 2021-05-25 | Artificial tears and therapeutic uses |
US18/364,692 Pending US20240108677A1 (en) | 2009-06-05 | 2023-08-03 | Artificial tears and therapeutic uses |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/376,374 Active US8496976B2 (en) | 2009-06-05 | 2010-06-03 | Artificial tears and therapeutic uses |
US13/931,281 Active US8679554B2 (en) | 2009-06-05 | 2013-06-28 | Artificial tears and therapeutic uses |
US14/166,589 Active 2031-03-12 US9821020B2 (en) | 2009-06-05 | 2014-01-28 | Artificial tears and therapeutic uses |
US15/791,158 Active 2031-03-02 US11045515B2 (en) | 2009-06-05 | 2017-10-23 | Artificial tears and therapeutic uses |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/364,692 Pending US20240108677A1 (en) | 2009-06-05 | 2023-08-03 | Artificial tears and therapeutic uses |
Country Status (24)
Country | Link |
---|---|
US (6) | US8496976B2 (en) |
EP (1) | EP2437762B1 (en) |
KR (1) | KR101778316B1 (en) |
CN (2) | CN102458430A (en) |
AU (1) | AU2010256652B2 (en) |
BR (1) | BRPI1011710B8 (en) |
CA (1) | CA2764802A1 (en) |
DK (1) | DK2437762T3 (en) |
ES (1) | ES2646338T3 (en) |
HK (1) | HK1214943A1 (en) |
HR (1) | HRP20171691T1 (en) |
HU (1) | HUE034213T2 (en) |
IL (1) | IL216800A (en) |
LT (1) | LT2437762T (en) |
MX (2) | MX358504B (en) |
MY (1) | MY172185A (en) |
NO (1) | NO2437762T3 (en) |
NZ (1) | NZ596932A (en) |
PL (1) | PL2437762T3 (en) |
PT (1) | PT2437762T (en) |
RU (1) | RU2589837C2 (en) |
SI (1) | SI2437762T1 (en) |
WO (1) | WO2010141648A2 (en) |
ZA (1) | ZA201108979B (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8569367B2 (en) | 2004-11-16 | 2013-10-29 | Allergan, Inc. | Ophthalmic compositions and methods for treating eyes |
KR101778316B1 (en) | 2009-06-05 | 2017-09-13 | 알러간, 인코포레이티드 | Artificial tears and therapeutic uses |
US8957048B2 (en) * | 2011-10-06 | 2015-02-17 | Allergan, Inc. | Compositions for the treatment of dry eye |
US9907826B2 (en) | 2011-12-07 | 2018-03-06 | Allergan, Inc. | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
PL2787968T3 (en) * | 2011-12-07 | 2020-08-24 | Allergan, Inc. | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
US9278132B2 (en) * | 2012-02-13 | 2016-03-08 | Bausch & Lomb Incorporated | Ophthalmic pharmaceutical compositions and methods of making and using same |
US10085960B2 (en) | 2012-03-30 | 2018-10-02 | Brien Holden Vision Institute | Methods and compositions for reducing ocular discomfort |
US9289494B2 (en) * | 2013-11-20 | 2016-03-22 | RestorTears, LLC | Method of treating ocular disorders with compounds found in Harderian gland secretions |
WO2016029034A1 (en) | 2014-08-20 | 2016-02-25 | Silk Technologies, Ltd. | Fibroin-derived protein composition |
AU2015353701B2 (en) * | 2014-11-25 | 2021-03-25 | Allergan, Inc. | Stabilized omega-3 ophthalmic compositions |
WO2017066429A1 (en) | 2015-10-14 | 2017-04-20 | Paul Gavaris | Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents |
AU2017267370B2 (en) | 2016-04-08 | 2021-07-08 | Cornell University | A method to enhance wound healing using silk-derived protein |
RS58292B1 (en) | 2016-07-07 | 2019-03-29 | Salvat Lab Sa | Ophthalmic composition comprising castor oil and medium chain triglyceride |
EP3496662A4 (en) | 2016-08-12 | 2019-10-30 | Silk Technologies Ltd. | Silk-derived protein for treating inflammation |
WO2018035469A1 (en) * | 2016-08-19 | 2018-02-22 | Akrivista, LLC | Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye |
GB201618175D0 (en) * | 2016-10-27 | 2016-12-14 | Warneford Healthcare Ltd | Pharmaceutical compositions |
KR20220153671A (en) * | 2017-06-30 | 2022-11-18 | 제니비젼 인크. | Formulations for hair growth |
US11622982B2 (en) | 2017-08-18 | 2023-04-11 | Akrivista Llc | Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye |
US11166997B2 (en) | 2018-07-27 | 2021-11-09 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
CN112888450A (en) | 2018-07-27 | 2021-06-01 | 强生外科视力公司 | Compositions and methods for treating the eye |
CA3106898A1 (en) | 2018-07-27 | 2020-01-30 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
US10966948B2 (en) | 2019-07-23 | 2021-04-06 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
BR112021000724A2 (en) | 2018-07-27 | 2021-04-13 | Johnson & Johnson Surgical Vision, Inc. | COMPOSITIONS AND METHODS FOR TREATING THE EYES |
WO2020021481A1 (en) | 2018-07-27 | 2020-01-30 | Johnson & Johnson Vision Care, Inc. | Compositions and methods for treating the eye |
US11197841B2 (en) | 2019-07-23 | 2021-12-14 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
US11045416B2 (en) | 2018-08-30 | 2021-06-29 | Johnson & Johnson Consumer Inc. | Topical compositions comprising Pichia anomala and retinol |
US11110051B2 (en) | 2018-08-30 | 2021-09-07 | Johnson & Johnson Consumer Inc. | Topical compositions comprising Pichia anomala and n-acetyl glucosamine |
KR20210009947A (en) | 2019-07-18 | 2021-01-27 | 윤영선 | Oxygen-introduced Ophthalmic compound, and a method for producing the same |
CN112823789B (en) | 2019-11-19 | 2024-05-10 | 强生外科视力公司 | Compositions and methods for treating eyes |
EP3824877A1 (en) | 2019-11-19 | 2021-05-26 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating the eye |
US11969451B2 (en) | 2019-11-19 | 2024-04-30 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
US11969454B2 (en) | 2019-11-19 | 2024-04-30 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
EP4059508A1 (en) | 2021-03-19 | 2022-09-21 | Johnson & Johnson Consumer Inc. | Methods of using compositions comprising an iceland moss extract |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56104814A (en) * | 1980-01-25 | 1981-08-20 | Kunihiro Okanoe | Preparation of eye drop |
US4649047A (en) | 1985-03-19 | 1987-03-10 | University Of Georgia Research Foundation, Inc. | Ophthalmic treatment by topical administration of cyclosporin |
US4839342A (en) | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
ATE109970T1 (en) | 1987-09-03 | 1994-09-15 | Univ Georgia Res Found | CYCLOSPORIN EYE REMEDY. |
BE1003578A4 (en) * | 1988-10-26 | 1992-04-28 | Sandoz Sa | New ophthalmic compositions of cyclosporine. |
US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
AU1172097A (en) | 1995-12-27 | 1997-07-28 | Rohto Pharmaceutical Co., Ltd. | Pharmaceutical composition containing trehalose |
US5981607A (en) * | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
GB0012597D0 (en) | 2000-05-25 | 2000-07-12 | Astrazeneca Ab | Formulation |
US7027446B2 (en) | 2001-07-18 | 2006-04-11 | P-Cube Ltd. | Method and apparatus for set intersection rule matching |
JP4284491B2 (en) | 2002-07-16 | 2009-06-24 | 豊和工業株式会社 | Piston outline machining data generator |
TWI335819B (en) * | 2002-12-24 | 2011-01-11 | Alcon Inc | Use of oculosurface selective glucocorticoid in the treatment of dry eye |
EP2343045A3 (en) * | 2003-02-24 | 2011-09-21 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
US20060251685A1 (en) | 2003-03-18 | 2006-11-09 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye |
US20040185068A1 (en) | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
KR20070040381A (en) | 2004-07-01 | 2007-04-16 | 셰펜스 아이 리써치 | Compositions and methods for treating eye disorders and conditions |
WO2006022291A1 (en) * | 2004-08-27 | 2006-03-02 | Senju Pharmaceutical Co, .Ltd. | Eyewash liquid for dry eye therapy |
US8569367B2 (en) * | 2004-11-16 | 2013-10-29 | Allergan, Inc. | Ophthalmic compositions and methods for treating eyes |
CN100562340C (en) * | 2005-06-17 | 2009-11-25 | 中国科学院上海药物研究所 | A kind of micro-emulsion type artificial tear |
US7288520B2 (en) | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
US7202209B2 (en) | 2005-07-13 | 2007-04-10 | Allergan, Inc. | Cyclosporin compositions |
US7297679B2 (en) | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
WO2008035246A2 (en) | 2006-07-28 | 2008-03-27 | Novagali Pharma Sa | Compositions containing quaternary ammonium compounds |
WO2008027341A2 (en) * | 2006-08-30 | 2008-03-06 | Merck & Co., Inc. | Topical ophthalmic formulations |
JP2010520210A (en) * | 2007-02-28 | 2010-06-10 | アーシエックス セラピューティックス, インコーポレイテッド | Methods and compositions for normalizing meibomian gland secretions |
CN101554369B (en) * | 2008-05-12 | 2012-07-25 | 陈亚玲 | External spraying agent and eye drop of compound oil nano-emulsion as well as preparation method thereof |
UA36915U (en) * | 2008-05-28 | 2008-11-10 | Львівський Національний Медичний Університет Ім. Данила Галицького | Eye drops for treating inflammatory diseases of choroids and dry keratoconjunctivitis caused by autoimmune processes |
IT1393419B1 (en) | 2009-03-19 | 2012-04-20 | Medivis S R L | OPHTHALMIC COMPOSITIONS OF OMEGA-3 AND OMEGA-6 POLYSATURATED FATTY ACIDS. |
US9480645B2 (en) | 2009-06-02 | 2016-11-01 | Abbott Medical Optics Inc. | Omega-3 oil containing ophthalmic emulsions |
KR101778316B1 (en) | 2009-06-05 | 2017-09-13 | 알러간, 인코포레이티드 | Artificial tears and therapeutic uses |
-
2010
- 2010-06-03 KR KR1020127000233A patent/KR101778316B1/en active IP Right Grant
- 2010-06-03 CA CA2764802A patent/CA2764802A1/en not_active Abandoned
- 2010-06-03 PL PL10724631T patent/PL2437762T3/en unknown
- 2010-06-03 EP EP10724631.6A patent/EP2437762B1/en not_active Revoked
- 2010-06-03 BR BRPI1011710A patent/BRPI1011710B8/en active IP Right Grant
- 2010-06-03 LT LTEP10724631.6T patent/LT2437762T/en unknown
- 2010-06-03 CN CN2010800348429A patent/CN102458430A/en active Pending
- 2010-06-03 MX MX2014012100A patent/MX358504B/en unknown
- 2010-06-03 CN CN201510225116.XA patent/CN104906170A/en active Pending
- 2010-06-03 WO PCT/US2010/037153 patent/WO2010141648A2/en active Application Filing
- 2010-06-03 US US13/376,374 patent/US8496976B2/en active Active
- 2010-06-03 AU AU2010256652A patent/AU2010256652B2/en active Active
- 2010-06-03 DK DK10724631.6T patent/DK2437762T3/en active
- 2010-06-03 PT PT107246316T patent/PT2437762T/en unknown
- 2010-06-03 MY MYPI2012000497A patent/MY172185A/en unknown
- 2010-06-03 NZ NZ596932A patent/NZ596932A/en unknown
- 2010-06-03 MX MX2011013007A patent/MX2011013007A/en active IP Right Grant
- 2010-06-03 ES ES10724631.6T patent/ES2646338T3/en active Active
- 2010-06-03 RU RU2011151468/15A patent/RU2589837C2/en active
- 2010-06-03 SI SI201031575T patent/SI2437762T1/en unknown
- 2010-06-03 NO NO10724631A patent/NO2437762T3/no unknown
- 2010-06-03 HU HUE10724631A patent/HUE034213T2/en unknown
-
2011
- 2011-12-06 IL IL216800A patent/IL216800A/en active IP Right Grant
- 2011-12-07 ZA ZA2011/08979A patent/ZA201108979B/en unknown
-
2013
- 2013-06-28 US US13/931,281 patent/US8679554B2/en active Active
-
2014
- 2014-01-28 US US14/166,589 patent/US9821020B2/en active Active
-
2016
- 2016-03-14 HK HK16102876.7A patent/HK1214943A1/en unknown
-
2017
- 2017-10-23 US US15/791,158 patent/US11045515B2/en active Active
- 2017-11-06 HR HRP20171691TT patent/HRP20171691T1/en unknown
-
2021
- 2021-05-25 US US17/329,586 patent/US20220008496A1/en not_active Abandoned
-
2023
- 2023-08-03 US US18/364,692 patent/US20240108677A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240108677A1 (en) | Artificial tears and therapeutic uses | |
KR20150038311A (en) | Compositions and treatment for eye diseases and disorder | |
US20210245512A1 (en) | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system | |
CN111182893A (en) | Ophthalmic composition comprising F6H8 | |
AU2017265181A1 (en) | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system | |
KR20210080388A (en) | Ophthalmic composition for the treatment of ocular surface damage and dryness symptoms | |
JP2007211008A (en) | Aqueous ophthalmic solution for preventing or ameliorating evaporation promotion-type dry eye | |
KR20160096376A (en) | Ophthalmic composition comprising hyaluronic acid, mineral oil and surfactants | |
NZ743307A (en) | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system | |
NZ743307B2 (en) | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALLERGAN, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GORE, ANURADHA V.;JORDAN, ROBERT S.;KROCK, KEVIN;AND OTHERS;REEL/FRAME:056343/0039 Effective date: 20090721 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |